We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+61.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$936M
AUM Growth
+$589M
(+170%)
Cap. Flow
+$339M
Cap. Flow
% of AUM
36.25%
Top 10 Holdings %
Top 10 Hldgs %
80.61%
Holding
67
New
28
Increased
19
Reduced
5
Closed
15
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
+$122M |
| 2 |
Perspective Therapeutics
CATX
|
+$37.6M |
| 3 |
ORKA
Oruka Therapeutics
ORKA
|
+$29.9M |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$20.3M |
| 5 |
Enliven Therapeutics
ELVN
|
+$18.3M |
Top Sells
| 1 |
CG Oncology
CGON
|
+$10.4M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$8.35M |
| 3 |
McKesson
MCK
|
+$7.81M |
| 4 |
Agilent Technologies
A
|
+$5.65M |
| 5 |
Pfizer
PFE
|
+$5.07M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0.39% |
| 3 | Consumer Discretionary | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dianthus Therapeutics
DNTH
$5.46B
| $361M | 38.62% |
4,208,368
+2,104,184
| +100% | +$122M |
|
|
ORKA
2
Oruka Therapeutics
ORKA
$5.23B
| $89.3M | 9.55% |
1,520,848
+860,424
| +130% | +$29.9M |
|
|
3
CG Oncology
CGON
$6.44B
| $87.2M | 9.32% |
1,288,948
-183,751
| -12% | -$10.4M |
|
|
JBIO
4
Jade Biosciences
JBIO
$1.33B
| $53.9M | 5.76% |
2,801,416
+1,400,708
| +100% | +$20.3M |
|
|
5
Perspective Therapeutics
CATX
$367M
| $48.8M | 5.22% |
12,099,998
+8,889,265
| +277% | +$37.6M |
|
|
6
Enliven Therapeutics
ELVN
$3.8B
| $32.2M | 3.44% |
800,000
+659,700
| +470% | +$18.3M |
|
7
Context Therapeutics
CNTX
$57.9M
| $24.9M | 2.66% |
9,996,534
+4,491,679
| +82% | +$10.5M |
|
8
Teva Pharmaceuticals
TEVA
$36.7B
| $20.6M | 2.2% |
650,100
+232,800
| +56% | +$7.49M |
|
9
Repligen
RGEN
$8.35B
| $18.4M | 1.96% |
155,600
+105,300
| +209% | +$14.7M |
|
|
PVLA
10
Palvella Therapeutics
PVLA
$2.18B
| $17.7M | 1.89% |
140,000
+120,700
| +625% | +$12.6M |
|
|
AKTS
11
Aktis Oncology
AKTS
$1.44B
| $17.2M | 1.83% |
+937,132
| New | +$18.2M |
|
12
Medtronic
MDT
$103B
| $16.8M | 1.79% |
200,000
+92,400
| +86% | +$8.85M |
|
13
Vir Biotechnology
VIR
$1.62B
| $14.8M | 1.59% |
+1,569,300
| New | +$12.5M |
|
14
Immunic
IMUX
$206M
| $13.9M | 1.48% |
736,935
+266,994
| +57% | +$2.39M |
|
15
DexCom
DXCM
$28.1B
| $11.6M | 1.24% |
+190,000
| New | +$13.2M |
|
16
Encompass Health
EHC
$10.9B
| $8.26M | 0.88% |
84,000
+52,400
| +166% | +$5.37M |
|
17
Boston Scientific
BSX
$64B
| $7.22M | 0.77% |
120,000
+5,500
| +5% | +$440K |
|
18
Tenax Therapeutics
TENX
$407M
| $6.94M | 0.74% |
+481,868
| New | +$6.52M |
|
19
Karyopharm Therapeutics
KPTI
$216M
| $6.44M | 0.69% |
927,482
+792,916
| +589% | +$6.04M |
|
20
Humana
HUM
$49B
| $5.91M | 0.63% |
+25,000
| New | +$5.12M |
|
21
Phathom Pharmaceuticals
PHAT
$881M
| $5.56M | 0.59% |
498,780
+292,704
| +142% | +$3.7M |
|
22
Gilead Sciences
GILD
$164B
| $5.4M | 0.58% |
+40,000
| New | +$5.6M |
|
|
MSLE
23
Satellos Bioscience
MSLE
$182M
| $5.27M | 0.56% |
+775,538
| New | +$7.62M |
|
|
TEM
24
Tempus AI
TEM
$10.3B
| $4.74M | 0.51% |
+90,000
| New | +$5.11M |
|
25
SCYNEXIS
SCYX
$48M
| $3.84M | 0.41% |
520,415
+260,207
| +100% | +$1.61M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH